Biosimilars: EMEA Wants Approvals
Executive Summary
European regulators’ guidelines on biosimilars show that they are serious about quickly approving cheaper follow-on biologics. The hurdles may come thereafter.
You may also be interested in...
Glide Pharmaceutical Technologies Ltd.
The UK's Glide Pharma has developed a needle-free, solid-dose drug delivery technology that's easy to use and applicable to both small and large molecules. In essence, tiny solid 'rods' of drug are simply pushed through the skin--no sharps, no blistering, and none of the storage issues associated with some liquid-dosed biologicals.
Why EPO Matters
Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.
Why EPO Matters
Dramatic events in the EPO market--roiled by patent fights, biosimilars, and next-generation products--are important not merely to the current EPO players. They affect nearly all large-molecule companies.